Lanreotide
Lanreotide is an FDA-approved somatostatin analog. Lanreotide is a cyclic octapeptide analog of somatostatin with high affinity for somatostatin receptor subtypes 2 and 5. Receptor activation inhibits growth hormone release from the pituitary and suppresses secretion of several gut hormones, and in neuroendocrine tumours also exerts direct antiproliferative effects.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 1096.3 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Long-acting somatostatin analog approved for acromegaly, for unresectable gastroenteropancreatic neuroendocrine tumours, and for carcinoid syndrome.
Peptide Library's Lanreotide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Sequence & molecular data
| Molecular formula | C54H69N11O10S2 |
|---|---|
| Molecular weight | 1096.3 g/mol |
| PubChem CID | 6918011 |
| FDA UNII | 0G3DE8943Y |
| ChEMBL | CHEMBL1201185 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Lanreotide is a cyclic octapeptide analog of somatostatin with high affinity for somatostatin receptor subtypes 2 and 5. Receptor activation inhibits growth hormone release from the pituitary and suppresses secretion of several gut hormones, and in neuroendocrine tumours also exerts direct antiproliferative effects. Its supersaturated aqueous depot formulation forms a subcutaneous reservoir that releases drug over several weeks.
Studies
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors
- The safety of lanreotide for neuroendocrine tumor
- Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors
- Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors
- Lanreotide autogel in acromegaly - a decade on
Regulatory & research status
Lanreotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Lanreotide: frequently asked questions
What is Lanreotide?
Long-acting somatostatin analog approved for acromegaly, for unresectable gastroenteropancreatic neuroendocrine tumours, and for carcinoid syndrome.
How does Lanreotide work?
Lanreotide is a cyclic octapeptide analog of somatostatin with high affinity for somatostatin receptor subtypes 2 and 5. Receptor activation inhibits growth hormone release from the pituitary and suppresses secretion of several gut hormones, and in neuroendocrine tumours also exerts direct antiproliferative effects.
Is Lanreotide FDA approved?
Yes. Lanreotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Lanreotide?
Compounds most often compared with Lanreotide include Octreotide, Pasireotide, Human Growth Hormone (Somatropin) and Lonapegsomatropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors — N Engl J Med, 2014External reference
- The safety of lanreotide for neuroendocrine tumor — Expert Opin Drug Saf, 2019External reference
- Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors — Expert Opin Pharmacother, 2016External reference
- Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors — Curr Oncol Rep, 2016External reference
- Lanreotide autogel in acromegaly - a decade on — Expert Opin Pharmacother, 2014External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Lanreotide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Lanreotide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →